Antituberculosis drug-induced hepatotoxicity in children

Por Donald, Peter R
Publicado em 2011

The University of Kansas High-Throughput Screening Laboratory. Part II: enabling collaborative drug-discovery partnerships through cutting-edge screening technology

Por McDonald, Peter R, Roy, Anuradha, Chaguturu, Rathnam
Publicado em 2011

The University of Kansas High-Throughput Screening Laboratory. Part I: meeting drug-discovery needs in the heartland of America with entrepreneurial flair

Por McDonald, Peter R, Roy, Anuradha, Chaguturu, Rathnam
Publicado em 2011

Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making

Por Roy, Anuradha, McDonald, Peter R., Sittampalam, Sitta, Chaguturu, Rathnam
Publicado em 2010

Screening of Natural Compounds as Activators of the Keap1-Nrf2 Pathway

Por Wu, Kai C, McDonald, Peter R, Liu, Jie, Klaassen, Curtis D
Publicado no Planta Med (2013)

Surveillance of Antituberculosis Drug Resistance Among Children From the Western Cape Province of South Africa—An Upward Trend

Por Schaaf, H. Simon, Marais, Ben J., Hesseling, Anneke C., Brittle, Wendy, Donald, Peter R.
Publicado em 2009

Identification of Chemosensitivity Nodes for Vinblastine through Small Interfering RNA High-Throughput Screens

Por Kitchens, Carolyn A., McDonald, Peter R., Shun, Tong Ying, Pollack, Ian F., Lazo, John S.
Publicado em 2011

Implementation of a High-Throughput Screen for Identifying Small Molecules to Activate the Keap1-Nrf2-ARE Pathway

Por Wu, Kai Connie, McDonald, Peter R., Liu, Jie Jerry, Chaguturu, Rathnam, Klaassen, Curtis D.
Publicado em 2012

Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies

Por De Jager, Veronique, van der Merwe, Lize, Venter, Amour, Donald, Peter R., Diacon, Andreas H.
Publicado no Antimicrob Agents Chemother (2017)

Suitability of Xpert MTB/RIF and Genotype MTBDRplus for Patient Selection for a Tuberculosis Clinical Trial

Por Friedrich, Sven O., Venter, Amour, Kayigire, Xavier A., Dawson, Rodney, Donald, Peter R., Diacon, Andreas H.
Publicado em 2011

Ensuring the Involvement of Children in the Evaluation of New Tuberculosis Treatment Regimens

Por Burman, William J, Cotton, Mark F, Gibb, Diana M, Walker, A. Sarah, Vernon, Andrew A, Donald, Peter R
Publicado em 2008

Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases

Por Hesseling Anneke C, Whitelaw Andrew, Marais Ben J, Schaaf H Simon, Eley Brian, Hussey Gregory D, Donald Peter R
Publicado em 2007-11-01

Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases

Por Schaaf, H Simon, Marais, Ben J, Whitelaw, Andrew, Hesseling, Anneke C, Eley, Brian, Hussey, Gregory D, Donald, Peter R
Publicado em 2007

Identification of Survival Genes in Human Glioblastoma Cells by Small Interfering RNA Screening

Por Thaker, Nikhil G., Zhang, Fang, McDonald, Peter R., Shun, Tong Ying, Lewen, Michael D., Pollack, Ian F., Lazo, John S.
Publicado em 2009

Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation

Por Polireddy, Kishore, Dong, Ruochen, McDonald, Peter R., Wang, Tao, Luke, Brendan, Chen, Ping, Broward, Melinda, Roy, Anuradha, Chen, Qi
Publicado no PLoS One (2016)

Compound Ranking Based on a New Mathematical Measure of Effectiveness Using Time Course Data from Cell-Based Assays

Por Diaz, Francisco J., McDonald, Peter R., Roy, Anuradha, Taylor, Byron, Price, Ashleigh, Hall, Jessica, Blagg, Brian S.J., Chaguturu, Rathnam
Publicado em 2013

Pharmacokinetics of para-Aminosalicylic Acid in HIV-Uninfected and HIV-Coinfected Tuberculosis Patients Receiving Antiretroviral Therapy, Managed for Multidrug-Resistant and Extens...

Por de Kock, Lizanne, Sy, Sherwin K. B., Rosenkranz, Bernd, Diacon, Andreas H., Prescott, Kim, Hernandez, Kenneth R., Yu, Mingming, Derendorf, Hartmut, Donald, Peter R.
Publicado em 2014

N-Acetyltransferase Genotypes and the Pharmacokinetics and Tolerability of para-Aminosalicylic Acid in Patients with Drug-Resistant Pulmonary Tuberculosis

Por Sy, Sherwin K. B., de Kock, Lizanne, Diacon, Andreas H., Werely, Cedric J., Xia, Huiming, Rosenkranz, Bernd, van der Merwe, Lize, Donald, Peter R.
Publicado no Antimicrob Agents Chemother (2015)

Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824

Por Diacon, Andreas H., Dawson, Rodney, du Bois, Jeannine, Narunsky, Kim, Venter, Amour, Donald, Peter R., van Niekerk, Christo, Erondu, Ngozi, Ginsberg, Ann M., Becker, Piet, Spigelman, Melvin K.
Publicado em 2012

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses

Por Zvada, Simbarashe P., Denti, Paolo, Donald, Peter R., Schaaf, H. Simon, Thee, Stephanie, Seddon, James A., Seifart, Heiner I., Smith, Peter J., McIlleron, Helen M., Simonsson, Ulrika S. H.
Publicado em 2014